keyword
MENU ▼
Read by QxMD icon Read
search

HER2 positive

keyword
https://www.readbyqxmd.com/read/28821197/regional-variability-in-percentage-of-breast-cancers-reported-as-positive-for-her2-in-california-implications-of-patient-demographics-on-laboratory-benchmarks
#1
Chieh-Yu Lin, Eugene E Carneal, Daphne Y Lichtensztajn, Scarlett L Gomez, Christina A Clarke, Kristin C Jensen, Allison W Kurian, Kimberly H Allison
Objectives: The expected regional variability in percent human epidermal growth factor receptor 2 (HER2)-positive breast cancers is not currently clear. Methods: Data from the 2006 to 2011 California Cancer Registry were examined by county and health service area. The influence of demographic and pathologic features was used in a multivariable logistic regression model to compare expected with observed HER2-positive percentages by region. Results: There was significant geographic variation by California counties (11...
September 1, 2017: American Journal of Clinical Pathology
https://www.readbyqxmd.com/read/28819024/trastuzumab-increases-her2-uptake-and-cross-presentation-by-dendritic-cells
#2
Victor A Gall, Anne V Philips, Na Qiao, Karen Clise-Dwyer, Alexander A Perakis, Mao Zhang, Guy Travis Clifton, Pariya Sukhumalchandra, Qing Ma, Sangeetha M Reddy, Dihua Yu, Jeffrey J Molldrem, George E Peoples, Gheath Alatrash, Elizabeth A Mittendorf
Early phase clinical trials evaluating CD8+ T cell-eliciting, HER2-derived peptide vaccines administered to HER2-positive breast cancer patients in the adjuvant setting suggest synergy between the vaccines and trastuzumab, the monoclonal antibody targeting the HER2 protein. Among 60 patients enrolled on clinical trials evaluating the E75+GM-CSF and GP2+GM-CSF vaccines, there have been no recurrences in patients vaccinated after receiving trastuzumab as part of standard therapy in the per treatment analyses conducted after a median follow-up of greater than 34 months...
August 17, 2017: Cancer Research
https://www.readbyqxmd.com/read/28818992/long-half-life-89-zr-labeled-radiotracers-can-guide-in-suite-percutaneous-molecular-imaging-pet-ct-guided-biopsies-without-reinjection-of-radiotracer
#3
Francois H Cornelis, Jeremy Durack, Neeta Pandit-Taskar, Gary A Ulaner, Jason S Lewis, Michael J Morris, Stephen B Solomon
Rationale: To evaluate the feasibility of in suite Zr89 labeled radiotracer positron emission tomography-computed tomography (PET/CT)-guided biopsies performed without reinjection. Methods: From 2013-2016, 12 patients (7 males, 5 females; mean age 61 years, range 40-75) with suspected metastatic prostate or breast carcinoma on either imaging or biochemical progression underwent 14 percutaneous biopsies after diagnostic PET/CT using (89)Zr labeled radiotracers (mean dose: 180MBq; range: 126-189MBq) targeting prostate specific membrane antigen (PSMA) (n = 7) or human epidermal growth factor receptor 2 (HER2) (n = 5)...
August 17, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28816986/efficacy-and-safety-of-endocrine-monotherapy-as-first-line-treatment-for-hormone-sensitive-advanced-breast-cancer-a-network-meta-analysis
#4
Jingwen Zhang, Yanhong Huang, Changyi Wang, Yuanfang He, Shukai Zheng, Kusheng Wu
BACKGROUND: Endocrine therapy was recommended as the preferred first-line treatment for hormone receptor-positive (HR+, i.e., ER+ and/or PgR+), human epidermal growth factor receptor-2-negative (HER2-) postmenopausal advanced breast cancer (ABC), but which endocrine monotherapy is optimal lacks consensus. We aimed to identify the optimal endocrine monotherapy with a network meta-analysis. METHODS: We performed a network meta-analysis for a comprehensive analysis of 6 first-line endocrine monotherapies (letrozole, anastrozole, exemestane, tamoxifen, fulvestrant 250 mg and 500 mg) for HR+ HER2- metastatic or locally advanced breast cancer in postmenopausal patients...
August 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28815451/all-her2-positive-tumors-are-not-created-equal
#5
EDITORIAL
Elizabeth A Mittendorf, Mariana Chavez-MacGregor
No abstract text is available yet for this article.
August 16, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28815327/molecular-characterization-and-heterogeneity-of-circulating-tumor-cells-in-breast-cancer
#6
Anna Jakabova, Zuzana Bielcikova, Eliska Pospisilova, Rafal Matkowski, Bartlomiej Szynglarewicz, Urszula Staszek-Szewczyk, Milada Zemanova, Lubos Petruzelka, Petra Eliasova, Katarina Kolostova, Vladimir Bobek
INTRODUCTION: This study analyzes peripheral blood samples from breast cancer (BC) patients. CTCs from peripheral blood were enriched by size-based separation and were then cultivated in vitro. The primary aim of this study was to demonstrate the antigen independent CTC separation method with high CTC recovery. Subsequently, CTCs enriched several times during the treatment were characterized molecularly. METHODS: Patients with different stages of BC (N = 167) were included into the study...
August 16, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28814476/phase-i-trial-of-the-androgen-receptor-modulator-cr1447-in-breast-cancer
#7
Martin Zweifel, Beat Thuerlimann, Salome Riniker, Patrik Weder, Roger von Moos, Olivia Pagani, Martin Bigler, Karin M Rothgiesser, Christiane Pilop, Hanne Hawle, Peter Brauchli, Coya Tapia, Wolfgang Schoenfeld, Cristiana Sessa
CR 1447 (4-hydroxytestosterone, 4-OHT) binds to the androgen receptor and has antiproliferative activity in both ER-positive and ER-negative/AR-positive breast cancer cells in pre-clinical studies. The objective of this first-in man trial was to evaluate safety and to determine the dose of CR1447, administered as an ointment, for Phase II. Escalating doses (100, 200, 400 mg) of CR1447 were administered topically on a daily basis to patients with ER-positive/AR-positive/HER2-negative advanced breast cancer pretreated with several lines of therapy...
August 16, 2017: Endocrine Connections
https://www.readbyqxmd.com/read/28813638/impact-of-70-gene-signature-use-on-adjuvant-chemotherapy-decisions-in-patients-with-estrogen-receptor-positive-early-breast-cancer-results-of-a-prospective-cohort-study
#8
Anne Kuijer, Marieke Straver, Bianca den Dekker, Annelotte C M van Bommel, Sjoerd G Elias, Carolien H Smorenburg, Jelle Wesseling, Sabine C Linn, Emiel J Th Rutgers, Sabine Siesling, Thijs van Dalen
Purpose Gene-expression profiles increasingly are used in addition to conventional prognostic factors to guide adjuvant chemotherapy (CT) decisions. The Dutch guideline suggests use of validated gene-expression profiles in patients with estrogen receptor (ER) -positive, early-stage breast cancer without overt lymph node metastases. We aimed to assess the impact of a 70-gene signature (70-GS) test on CT decisions in patients with ER-positive, early-stage breast cancer. Patients and Methods In a prospective, observational, multicenter study in patients younger than 70 years old who had undergone surgery for ER-positive, early-stage breast cancer, physicians were asked whether they intended to administer adjuvant CT before deployment of the 70-GS test and after the test result was available...
August 20, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28811974/ex-vivo-assessment-of-drug-response-on-breast-cancer-primary-tissue-with-preserved-microenvironments
#9
Manuele G Muraro, Simone Muenst, Valentina Mele, Luca Quagliata, Giandomenica Iezzi, Alexandar Tzankov, Walter P Weber, Giulio C Spagnoli, Savas D Soysal
Interaction between cancerous, non-transformed cells, and non-cellular components within the tumor microenvironment plays a key role in response to treatment. However, short-term culture or xenotransplantation of cancer specimens in immunodeficient animals results in dramatic modifications of the tumor microenvironment, thus preventing reliable assessment of compounds or biologicals of potential therapeutic relevance. We used a perfusion-based bioreactor developed for tissue engineering purposes to successfully maintain the tumor microenvironment of freshly excised breast cancer tissue obtained from 27 breast cancer patients and used this platform to test the therapeutic effect of antiestrogens as well as checkpoint-inhibitors on the cancer cells...
2017: Oncoimmunology
https://www.readbyqxmd.com/read/28811185/the-effect-of-receptor-status-on-mastectomy-and-contralateral-prophylactic-mastectomy-rates-in-early-stage-invasive-breast-carcinoma
#10
Sunil W Dutta, Daniel M Trifiletti, Surbhi Grover, Kara D Romano, Einsley-Marie Janowski, Shayna L Showalter
BACKGROUND: There is an established relationship between hormone receptor (HR; estrogen and/or progesterone receptors) status, HER2 status, and locoregional recurrence. The purpose of this study was to analyze how HR and HER2 receptor status have influenced the surgical management trends among patients with early stage breast cancer. PATIENTS AND METHODS: The National Cancer Database was queried for patients with cT1 to cT3, cN0, and cM0 breast carcinoma from 2004 to 2012...
June 29, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28810292/-clinicopathologic-features-of-mammary-microglandular-adenosis-with-carcinoma-a-study-of-5-cases
#11
W Chen, C Wang, Z H Zhang, W M Zhang, Y Xu, G X Song
Objective: To study the clinicopathologic, immunohistochemical features, differential diagnoses and prognosis of mammary microglandular adenosis with carcinoma (MGACA) with micropapillary pattern. Methods: Five cases of MGACA were collected from 2010 to 2016 and reviewed for their clinical, histologic features and outcome.EnVision method were done for S-100 protein, cytokeratin (CK), p63, Calponin, smooth muscle myosin heavy chain (SMMHC), PR, ER and HER2. Results: Histologically, microglandular adenosis(MGA), atypical MGA (AMGA) and invasive carcinoma were seen in all five cases of MGACA...
August 8, 2017: Zhonghua Bing Li Xue za Zhi Chinese Journal of Pathology
https://www.readbyqxmd.com/read/28809784/folate-receptor-positive-gynecological-cancer-cells-in-vitro-and-in-vivo-characterization
#12
Klaudia Siwowska, Raffaella M Schmid, Susan Cohrs, Roger Schibli, Cristina Müller
The folate receptor (FR) is expressed in a variety of gynecological cancer types. It has been widely used for tumor targeting with folic acid conjugates of diagnostic and therapeutic probes. The cervical KB tumor cells have evolved as the standard model for preclinical investigations of folate-based (radio) conjugates. In this study, a panel of FR-expressing human cancer cell lines-including cervical (HeLa, KB, KB-V1), ovarian (IGROV-1, SKOV-3, SKOV-3.ip), choriocarcinoma (JAR, BeWo) and endometrial (EFE-184) tumor cells-was investigated in vitro and for their ability to grow as xenografts in mice...
August 15, 2017: Pharmaceuticals
https://www.readbyqxmd.com/read/28809778/reprimo-a-potential-p53-dependent-tumor-suppressor-gene-is-frequently-hypermethylated-in-estrogen-receptor-%C3%AE-positive-breast-cancer
#13
Kurt Buchegger, Ismael Riquelme, Tamara Viscarra, Carmen Ili, Priscilla Brebi, Tim Hui-Ming Huang, Juan Carlos Roa
Aberrant DNA methylation is a hallmark of many cancers. Currently, there are four intrinsic molecular subtypes in breast cancer (BC): Luminal A, B, Her2-positive, and triple negative (TNBC). Recently, The Cancer Genome Atlas (TCGA) project has revealed that Luminal subtypes have higher levels of genome-wide methylation that may be a result of Estrogen/Estrogen receptor α (E2/ERα) signaling pathway activation. In this study, we analyze promoter CpG-island (CGIs) of the Reprimo (RPRM) gene in breast cancers (n = 77), cell lines (n = 38), and normal breast tissue (n = 10) using a MBDCap-seq database...
August 15, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28808873/elevated-hu-antigen-receptor-hur-expression-is-associated-with-tumor-aggressiveness-and-poor-prognosis-but-not-with-cox-2-expression-in-invasive-breast-carcinoma-patients
#14
Constantinos Giaginis, Anastasia Sampani, Iolly Kotta-Loizou, Ioanna Giannopoulou, Eugene Danas, Ekaterini Politi, Gerasimos Tsourouflis, Gregorios Kouraklis, Efstratios Patsouris, Antonios Keramopoulos, Lydia Nakopoulou, Stamatios Theocharis
Hu-antigen R (HuR), a RNA-binding protein, is considered to play a crucial role in tumor development and progression by stabilizing or regulating a group of cellular mRNAs of cancer-related genes, such as cyclooxygenase-2 (COX-2). The present study aimed to evaluate the clinical significance of HuR and COX-2 expression in invasive breast carcinoma. HuR and COX-2 protein expression was assessed immunohistochemically on paraffin-embedded breast cancer tissue sections obtained from 121 patients and was statistically analyzed with clinicopathological parameters, estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2), as well as with tumor cells' proliferative capacity and overall and disease-free patients' survival...
August 14, 2017: Pathology Oncology Research: POR
https://www.readbyqxmd.com/read/28808484/er%C3%AE-and-er%C3%AE-co-expression-an-indicator-of-aggressive-tumors-and-hormonal-sensitivity
#15
Mohamed Oueslati, Ilhem Bittaieb, Nadia Sassi, Awatef Ben Jemaa, Amor Gamoudi, Khaled Rahal, Ridha Oueslati
The estrogen receptors (ERs) ERα and ERβ are important factors in breast cancer progression. Nevertheless, the molecular interplay between ERα and ERβ and its clinical significance in breast cancer is controversial. The establishment of a clear association is required; therefore, the current study analyzed the expression patterns of ERα and ERβ in 32 breast tumor tissues using reverse transcription-quantitative polymerase chain reaction. Furthermore, human epidermal growth factor receptor 2 (HER2) and the Ki-67 status were detected by immunohistochemistry...
August 2017: Oncology Letters
https://www.readbyqxmd.com/read/28806416/the-impact-of-malignant-nipple-discharge-cytology-ndc-in-surgical-management-of-breast-cancer-patients
#16
Isabella Castellano, Jasna Metovic, Davide Balmativola, Laura Annaratone, Nelson Rangel, Elena Vissio, Riccardo Arisio, Luigia Macrì, Carla Pecchioni, Ivana Sarotto, Francesca Montarolo, Francesca Muscarà, Caterina Marchiò, Paola Cassoni, Janina Kulka, Anna Sapino
BACKGROUND: The role of nipple discharge cytology (NDc) in the surgical management of breast cancer patients is unclear. We aimed: (i) to evaluate the effect of malignant NDc on the surgical approach to the nipple-areola complex, and (ii) to verify the association between malignant NDc and nipple malignancy. METHODS: We retrospectively analyzed a case series of 139 patients with NDc who underwent breast surgery. The clinical and histological findings, types of surgery with emphasis on nipple-areola complex amputation, immunohistochemical phenotypes of the carcinomas and measurements of the tumor-nipple distance were recorded...
2017: PloS One
https://www.readbyqxmd.com/read/28800870/recent-advances-in-her2-positive-breast-cancer-epigenetics-susceptibility-and-therapeutic-strategies
#17
REVIEW
Heena Singla, Abhilash Ludhiadch, Raman Preet Kaur, Harish Chander, Vinod Kumar, Anjana Munshi
HER2 amplification/overexpression accounts for aggressive clinical features of HER2 positive breast cancer. Epigenetic changes including DNA methylation, histone modifications and ncRNAs/miRNAs are associated with regulation of DNA chromatin and specifically, gene transcription. Hence, these produce eminent effects upon proto-oncogenes, tumor-suppressors and key cancer-regulatory signaling pathways. Understanding of epigenomic regulation of HER2 overexpression and signaling may help uncover the unmatchable physiology of HER2 gene/protein...
August 1, 2017: European Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/28799536/estrogen-receptor-esr1-mutation-in-bone-metastases-from-breast-cancer
#18
Stephan Bartels, Matthias Christgen, Angelina Luft, Sascha Persing, Kai Jödecke, Ulrich Lehmann, Hans Kreipe
Activating mutations of estrogen receptor α gene (ESR1) in breast cancer can cause endocrine resistance of metastatic tumor cells. The skeleton belongs to the metastatic sides frequently affected by breast cancer. The prevalence of ESR1 mutation in bone metastasis and the corresponding phenotype are not known. In this study bone metastases from breast cancer (n=231) were analyzed for ESR1 mutation. In 27 patients (12%) (median age 73 years, range: 55-82 years) activating mutations of ESR1 were detected. The most frequent mutation was p...
August 11, 2017: Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc
https://www.readbyqxmd.com/read/28799059/her2-intratumoral-heterogeneity-is-independently-associated-with-incomplete-response-to-anti-her2-neoadjuvant-chemotherapy-in-her2-positive-breast-carcinoma
#19
Yanjun Hou, Hiroaki Nitta, Lai Wei, Peter M Banks, Bryce Portier, Anil V Parwani, Zaibo Li
PURPOSE: Anti-HER2 neoadjuvant chemotherapy has been widely used in HER2-positive breast cancer patients; however, pathologic complete response (pCR) is achieved in only 40-50% of patients. The aim of this study was to investigate the association of HER2 intratumoral heterogeneity (ITH) with response to anti-HER2 neoadjuvant chemotherapy. METHODS: Assessment of HER2 ITH was performed on whole tissue sections of pre-treatment samples from a cohort of 64 invasive breast carcinoma cases originally considered positive for HER2 and treated with anti-HER2 neoadjuvant chemotherapy...
August 10, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28798274/disparities-of-trastuzumab-use-in-resource-limited-or-resource-abundant-regions-and-its-survival-benefit-on-her2-positive-breast-cancer-a-real-world-study-from-china
#20
Jianbin Li, Shusen Wang, Yongsheng Wang, Xiaojia Wang, Haibo Wang, Jifeng Feng, Qingyuan Zhang, Tao Sun, Quchang Ouyang, Yongmei Yin, Yinhua Liu, Cuizhi Geng, Min Yan, Zefei Jiang
BACKGROUND: Trastuzumab is a key component of therapy for human epidermal growth receptor 2 (HER2) positive breast cancer. Because real-world data are lacking, the present research was conducted to evaluate the the actual use of and the effectiveness of trastuzumab in the real world in China. METHODS: Inpatients with HER2 positive invasive breast cancer from 13 hospitals in Eastern China (2010-2015, n = 1,139) were included in this study. We aimed to assess the actual use of trastuzumab and to evaluate potential efficacy from trastuzumab in real-world research...
August 10, 2017: Oncologist
keyword
keyword
75017
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"